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Abstract: Heart failure has been singled out as an emerging epidemic, which could be the 
result of increased incidence and/or increased survival leading to increased prevalence. 
Knowledge of the responsibility of each factor in the genesis of the epidemic is crucial for 
prevention. Population-based studies have shown that, over time, the incidence of heart 
failure remained overall stable, while survival improved. Therefore, the heart failure 
epidemic is chiefly one of hospitalizations. Data on temporal trends in the incidence and 
prevalence of heart failure according to ejection fraction and how it may have changed 
over time are needed while interventions should focus on reducing the burden of 
hospitalizations in hear failure.  
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1. Heart Failure: An Epidemic in Need of Investigation  
 
Heart failure has been singled out as an emerging epidemic [1]. The Merriam-Webster dictionary 
defines epidemic as “an outbreak or product of sudden rapid spread, growth, or development; 
specifically: a natural population suddenly and greatly enlarged.” This may be occurring as a result of 
increased incidence, increased survival leading to increased prevalence or both factors combined. 
Knowledge of the respective responsibility of each of these factors in the genesis of the heart failure 
epidemic is crucial for prevention strategies. To identify studies for this review, we searched the 
Medline database for literature with
  the subject headings “heart failure, epidemiology prevalence, 
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incidence, trends” between 2005 and present. We identified 612 articles from which we selected the 
ones that form the basis of this article after reviewing the abstracts for relevance to the topic. 
2. Classification and Definitions  
The 2005 American Heart Association/American College of Cardiology guidelines [2] define heart 
failure as “a complex clinical syndrome that can result from any structural or functional cardiac 
disorder that impairs the ability of the ventricle to fill or eject blood”. The guidelines underscore that 
“it is largely a clinical diagnosis that is based on a careful history and physical examination”. These 
statements emphasize that heart failure is a syndrome and not a disease that that its diagnosis, which 
relies on a clinical evaluation, is quite challenging. To investigate the heart failure epidemic, 
standardized criteria that can be used on a large scale for ascertainment through medical records   
are needed.  
2.1. Presence of Heart Failure 
Several criteria have been proposed, including the Framingham criteria [3], the Boston criteria [4], 
the Gothenburg criteria [5] and the European Society of Cardiology criteria [6]. As shown in Table 1, 
all rely on similar indicators of symptoms and elevated filling pressures and combine data from the 
medical history, physical examination and chest X-ray. 
It is important to note that the European Society of Cardiology criteria  [6] require objective 
evidence of cardiac dysfunction. This is feasible in population sciences solely when uniformly used, 
which is still infrequently the case even in contemporary practice  [7-10]. When the Boston and 
Framingham criteria were compared against the masked assessment of a cardiologist [11],  their 
sensitivity was excellent at 100%. The specificity of the Framingham score and its positive predictive 
value were lower than those of the Boston score for definite heart failure, but it provided greater 
sensitivity to diagnose possible heart failure. Altogether, five of the six scores studied by   
Mosterd et al.  [11] were broadly similar for the detection of heart failure. It should be noted however 
that the sample size was small thereby limiting the ability to detect differences across scores. Some 
authors recommended the use of the Boston criteria over other criteria for the diagnosis of HF in older 
adults due to their construct validity and improved prediction of adverse outcomes  [12]. The 
Cardiovascular Health Study criteria rely on a panel of physicians that assign a diagnosis of heart 
failure by reviewing data on history, physical examination, chest radiogram report and medication  
use [13]. The comparison of the Framingham criteria to the Cardiovascular Health Study criteria 
yielded similar results [13]. Altogether, the Framingham criteria offer good performance. As they are 
unaffected by time and use of diagnostic tests, they are well suited for studies of secular trends. 
Clinical cases of heart failure not meeting validation criteria are also important to capture in studies as 
they contribute to the epidemic and to use of health care resources.  
2.2. Systolic and Diastolic Heart Failure 
Once the diagnosis of heart failure is established, further classification requires the understanding of 
the parameters of left ventricular function to understand the physiology of the heart failure syndrome 
in each patient.  Int. J. Environ. Res. Public Health 2010, 7          
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Table 1. Heart failure diagnostic criteria. 
Framingham [3] Boston [4] European Society of 
Cardiology [60] 
Gothenburg Score [5] 
Item and method of assessment 
MAJOR CRITERIA 
Paroxysmal nocturnal dyspnea or 
orthopnea 
Neck vein distension 
Rales 
Cardiomegaly 
Acute pulmonary edema 
S3 gallop 
Increased venous pressure>16cm 
water 
Circ.time >25 sec 
Hepatojugular reflux 
 
MINOR CRITERIA 
Ankle edema 
Night cough 
Dyspnea on exertion 
Hepatomegaly 
Pleural effusion 
Vital capacity decreased 1/3 from 
maximum 
Tachycardia rate of >120/min) 
 
MAJOR OR MINOR CRITERION 
Weight loss>4.5 kg in 5 days in 
response to treatment 
 
HEART FAILURE present with 2 
major or 1 major and 2 minor criteria 
CATEGORY I: History
Rest dyspnea (4pts) 
Orthopnea (4pts) 
Paroxysmal nocturnal dyspnea (3 pts) 
Dyspnea on walking on level (2pts) 
Dyspnea on climbing (1pt) 
 
CATEGORY II: Physical examination 
Heart rate abnormality (1-2pts) 
Jugular venous pressure elevation (1-2 pts) 
Lung crackles (1-2pts) 
Wheezing (3 pts) 
Third heart sound (3 pts) 
 
CATEGORY III: Chest radiography 
Alveolar pulmonary edema (4 pts) 
Interstitial pulmonary edema (3 pts) 
Bilateral pleural effusions (3 pts) 
Cardiothoracic ratio>0.50 (3 pts) 
Upper-zone flow redistribution (2 pts) 
 
Definite HEART FAILURE 8-12 pts, possible 
5-7pts, unlikely 4 pts or less 
1.Symptoms of heart failure (at 
rest or during exercise) 
and 
2. Objective evidence of cardiac 
dysfunction (at rest) 
and 
3. Response to treatment 
directed towards heart failure (in 
cases where diagnosis is in 
doubt). 
 
Criteria 1 and 2 should be 
fulfilled in all cases 
CARDIAC SCORE 
History of heart
disease (1-2pts) 
Self-report 
Angina
(1-2pts) 
Self-report 
Edema (1pt) Self-report 
Nocturnal Dyspnea 
(1pt) 
Self-report 
Rales (1pt) Physical exam 
Atrial fibrillation 
(1pt) 
ECG 
PULMONARY SCORE 
History of Chronic 
bronchitis/asthma(
1-2pts)
Self-report 
Cough, phlegm, or 
wheezing 
(1pt)
Self-report 
Rhonchi (2pts) Physical exam 
Cardiac and pulmonary score are 
calculated and used to differentiate 
Cardiac form pulmonary dyspnea Int. J. Environ. Res. Public Health 2010, 7          
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The first step is the assessment of left ventricular ejection fraction to classify heart failure into heart 
failure with preserved or reduced ejection fraction.  
While a reduced ejection fraction identifies systolic heart failure, different thresholds to define 
preserved ejection fraction have been recommended by different groups as shown in Table 2. In the 
Framingham Heart Study  [14] and Olmsted County Study  [15-19], the cut-off of 50% is used as 
recommended by the American Heart Association and American College of Cardiology 
guidelines [20]. While 55% was recommended in the recent American Society of Echocardiography 
guidelines [21], 50% remains the most commonly used cut-off and is recommended for use until there 
are more data to support another limit [22,23]. It is important to be mindful in this context of the 
arbitrary nature of such a threshold and of the variability of imaging studies that enable to determine 
this cut-point [24]. 
Table 2. Cut-points used to define preserved ejection fraction in selected studies. 
Author, reference  Study  EF cut-off 
Yusuf, 2003 Lancet [121]  CHARM Preserved trial  40% 
Lenzen, 2004 EHJ [122]  Euro HF survey  40% 
Paulus 1998 EHJ [122]  EPICA Study  45% 
Bhatia, 2006 NEJM [123]  EFFECT Study  >50 vs. <40 
Zile, 2004 NEJM [28]  Multicenter study  >50% 
Varadarajan, 2003 J Card 
Failure [124] 
Single center hospital-based study  ≥55% 
Kitzman, J. AM. MED. 
ASSOC.2002 [25] 
Cardiovascular Health Study  ≥50% 
Cortina, 2001 Am. J. 
Cardiol. [125] 
Asturias  ≥50% 
Devereux 2000 Am. J. 
Cardiol. [97] 
Strong Heart Study  >54% 
Vasan 2000 Circulation [14]  Framingham Heart Study  >50% 
 
Conversely, heart failure with an ejection fraction of 50% or greater in the absence of major valve 
disease defines heart failure with preserved systolic function  [14]. Using this threshold, ejection 
fraction is preserved in more than half of heart failure cases in the community [25,26]. To further 
classify subjects with heart failure and preserved ejection fraction, several criteria have been 
proposed  [14,22,27], and the need to assess diastolic function with catheterization versus 
echocardiography-Doppler to define diastolic heart failure remains controversial [14,22,23,28-30]. 
Invasive measurements with conductance catheters have historically been considered the gold 
standard to measure filling pressures [31]. However, as with all invasive approaches, it carries intrinsic 
risks, is seldom used in practice  [10] and is not feasible for population studies. While magnetic 
resonance imaging (MRI) is an excellent tool to assess cardiac volumes and mass [32], its use to 
evaluate diastolic function is presently not established  [33,34]. Thus, echocardiography-Doppler is 
currently the most feasible approach to assess diastolic function. Its results will likely have the most 
relevance to contemporary practice, as echocardiography-Doppler examination is a Class I indication 
(“conditions for which there is evidence and/or general agreement that a given procedure or treatment Int. J. Environ. Res. Public Health 2010, 7          
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is beneficial…”) in the heart failure guidelines [2] and left ventricular function assessment is a core 
performance measure for heart failure under the Joint Commission on Accreditation of Heath Care 
Organizations (JCAHO) [35]. In the past, Doppler indices for diastolic function have been criticized 
for their complexity, dependency on loading conditions and limited reproducibility [23,36,37]. The 
development and validation of Tissue Doppler Imaging (TDI) has been an important advance which, 
combined with mitral inflow measurements, provides a feasible and reproducible approach to assess 
filling pressures  [23,38-45]. These techniques enable classifying diastolic function into mutually 
exclusive categories, indicative of progressive elevation of filling pressures [26]. Several algorithms 
have been proposed including recently by the American Society of Echocardiography  [46]. The 
distinction between the existing sets of criteria should not obscure the fact that the basic measurements 
are similar such that it is important for the user to select the algorithm that he/she is most comfortable 
with based on the performance of the laboratory where the measurements are to be performed.  
Regardless of the measurements consideration, the mechanistic link between the elevation of filling 
pressures and the disease process is also controversial. Indeed, the causal role of intrinsic diastolic 
dysfunction (impaired relaxation and increased diastolic stiffness) [28] was challenged against that of 
altered ventricular-vascular coupling [47-49]. As underscored [48,50], the altered ventricular-vascular 
coupling hypothesis needs to be considered cautiously as heart failure with normal ejection fraction is 
likely a heterogeneous entity within the heart failure syndrome. Further, evaluating the putative role of 
other mechanisms requires complex measures that cannot be easily implemented in large scale 
epidemiology studies. One additional issue that must be considered is pulmonary hypertension. 
Pulmonary hypertension is frequent and often severe in heart failure with preserved ejection fraction. 
Although pulmonary venous hypertension contributes to pulmonary arterial hypertension, it does not 
always fully account for its severity, suggesting that a component of pulmonary arterial hypertension 
also plays a role [51]. Importantly, these mechanisms are not exclusive of one another and measuring 
diastolic function as can be done by echocardiography- Doppler is an important step towards 
improving our understanding of the heart failure syndrome [52].  
 
3. Incidence and Prevalence of Heart Failure 
 
As measured by Vital Statistics, the burden of heart failure and its societal cost are enormous, 
thereby epitomizing a public health problem as underscored in guidelines from the American Heart 
Association and American College of Cardiology [2]. Indeed, heart failure is the single most frequent 
cause of hospitalization in persons 65 years of age or older, and approximately 4.9 million Americans 
carry this diagnosis [53]. National Hospital Discharge Survey data from 1979 to 2004 indicate that the 
number of hospitalizations with any mention of heart failure tripled from 1,274,000 in 1979 to 
3,860,000 in 2004 [54]. As hospitalization statistics are event-based, not person-based, this allows 
multiple hospitalizations for the same individual to be counted without distinguishing between first 
and subsequent admission such that incidence cannot be derived from such data. Data on the 
prevalence and particularly the incidence of heart failure are relatively sparse and lack consistency as 
shown in Table 3. Several observations can be made from the review of this table. Firstly, several 
estimates are derived from hospital discharges. Further, the diagnoses are not always validated using 
standardized criteria, and shifts in hospital discharge diagnoses preferences after the introduction of the Int. J. Environ. Res. Public Health 2010, 7          
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Diagnosis-Related Groups payment systems have been documented  [55,56]. For heart failure in 
particular, the potential for “upcoding” of discharge diagnoses due to reimbursement incentives is well 
documented [57]. Thus, national statistics and claims data are inadequate to assess the burden of heart 
failure. Secondly, inpatient data may not capture all cases of heart failure as care is increasingly 
delivered in the outpatient setting [58]. Studies using surveys of physicians or self-report are by design 
more inclusive in their ascertainment. They reported relatively broad ranges of prevalence without 
validation. When validation was carried out, approaches have ranged from medical record review and 
adjudication as in the Cardiovascular Health Study [59] to the use of criteria such as the Framingham, 
Boston, or European Society of Cardiology criteria [3,4,60]. Using standardized criteria, the incidence 
of heart failure in an earlier study from Framingham was between 1.4 and 2.3 per 1000/year among 
persons 29 to 79 years old [3]. However, the size of the cohort inherently limits power to analyze 
secular trends in this report. Among the studies of secular trends [61-66], few [61,65,67,68] included 
outpatient data. Others used hospitalized cases without validation, and are thus subject to secular 
changes in hospitalization practices and coding patterns, which likely confound time trends in 
incidence. It should not be surprising therefore that their results differ. Croft [62], comparing the rates 
of initial hospitalization for heart failure using Medicare hospital claims in 1986 and 1993, reported an 
increase in the initial hospitalization for heart failure, while acknowledging limitations related to the 
lack of validation and possible incomplete ascertainment of incidence. Conversely, Stewart [63,64] 
suggested that the heart failure epidemic, as measured by trends in hospitalization in Scotland in the 
1990s, had “leveled off”. These data suffer from similar limitations, i.e., lack of validation and sole use 
of inpatient data. They, however, prompt the question of whether the stabilization of the heart failure 
hospitalization rates could be offset by increasing out patient care practice. Data from the Henry Ford 
Health system, a managed care organization [65], indicated that the prevalence of heart failure was 
increasing over time but did not detect any secular change in the incidence or mortality of heart failure. 
Reports from the Framingham Heart Study [68] and the Olmsted County Study [67] indicate that when 
outpatient heart failure is included, as is the case in these population-based studies, over time the 
incidence of heart failure remained stable [67] or even declined in women [68]. It should be noted that, 
while the interpretation and informal comparison of trends across studies is appropriate, as adjustment 
approaches differ, the absolute numbers cannot be compared. Importantly, the trends noted among the 
elderly are different underscoring the importance of careful consideration of age in the evaluation of 
the burden of heart failure. Indeed, data from the Kaiser Permanente system comparing the incidence 
of heart failure in 1970 to 1974 and 1990 to 1994 among persons 65 years old or greater indicated that 
the age-adjusted incidence increased by 14% over time and was greater for older persons and for 
men [69]. The Framingham and Olmsted County studies have shown trends toward increasing heart failure 
incidence among older persons contrasting with trends among younger persons. This pattern of increasing 
trends among older persons in three carefully conducted population studies is important to note given the 
aging of the population. While these reports provided needed insights into the heart failure epidemic, 
most studies pertain to white subjects, and data on the burden of heart failure in diverse populations are 
urgently needed. This underscores the imperative for continued community surveillance of heart 
failure in diverse populations [57,70]. Data on the incidence and prevalence of heart failure according 
to ejection fraction and how it may have changed over time are very limited. The available evidence 
suggests that the prevalence of heart failure with preserved ejection fraction increased over time [15].  Int. J. Environ. Res. Public Health 2010, 7          
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Table 3. Selected studies reporting on the incidence and prevalence of heart failure 
(*denotes studies reporting on time trends). 
Author Years Incidence  Prevalence  Population  source  Diagnostic 
criteria 
Gibson [126]  1962-64  ---  1%  Rural US counties 
Whites 
All ages, not adjusted 
Survey of Physicians 
No validation 
Schocken [127]  1971-75  ---  1-2%  NHANES I – Survey 
Ages 1-74 years, not 
adjusted  
Self-report  
No validation 
Senni [61]  1981, 1991  3/1000/yr  ---  Olmsted County 
All ages, age adjusted 
Mostly whites 
Framingham 
criteria 
Ho [128]  1980’s  Women 1.4/1000/yr  
Men 2.3/1000/yr 
0.8%  Framingham Heart Study 
Age adjusted 
Framingham 
criteria 
Croft* [62]  1986, 1993  White 24.6/1000/yr 
Black 26.1/1000/yr 
--- Medicare  enrollees 
First hospitalization 
Age adjusted 
Discharge 
diagnoses  
No validation 
Remes [129]  1986-88  Women 1.0/1000/yr 
Men 4.0/1000/yr 
---  In and out patient 
national registries 
Age adjusted 
Boston and 
Framingham 
criteria 
Cowie [99]  1995-96  Women 1.2/1000/yr 
Men 1.4/1000/yr 
--- Geographically  defined 
in UK 
In- and out-patient 
All ages, not adjusted 
European 
Society of 
Cardiology 
criteria 
Gottdiener [101]  1990-96  Non black 19/1000/yr 
Black 19/1000/yr  
Women 15/1000/yr 
Men 26/1000/yr 
 Cardiovascular  Health 
Study 
Age 65-100, age adjusted  
Self-report 
Adjudication 
committee 
Stewart* [63, 64]  1990-96  Women 1.3-1.9 
/1000/yr 
Men 1.27-2.2/1000/yr 
--- Hospital  discharge 
diagnoses  
All ages, not adjusted 
No validation 
Davies MK [130]  1995-99  ---  2-3%  Random sample  
UK population 
Ages > 45 , not adjusted 
European 
Society of 
Cardiology 
criteria 
Nielsen OW [131]  1993-95  ---  0.5-12%  General practice 
population  
Ages > 50 , not adjusted 
Boston criteria 
McCullough * [65]  1989-99  Women 3.7-4.2 
/1000/yr 
Men 4.0-3.7/1000/yr 
Women 3.7-
14.3 /1000 
Men 4.0-
14.5/1000/ 
Henry Ford Health 
System  
50% Whites 
Age adjusted 
Framingham 
/NHANES in a 
sample 
Levy*  [68]  1950-99  ~5/1000/yr  ---  Framingham Heart Study 
Age adjusted 
Mostly whites 
Framingham 
criteria 
Roger*  [67]  1979-2000  ~3/1000/yr  ---  Olmsted County 
Age adjusted  
Mostly whites 
Framingham 
criteria 
Barker [69]  1970-1974 
 
------------ 
1990-1994 
Women 8.6 /1000/yr 
Men 11.7/1000/yr 
------------------------- 
Women 11.8 /1000/yr 
Men 12.7/1000/yr 
--- Kaiser  Permanente 
Age adjusted  
Mostly whites 
Framingham 
criteria 
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4. Mortality of Heart Failure  
 
The prognosis of heart failure is poor with reported survival estimates of 50% and 10% at 5 and 10 
years, respectively [71-73], and left ventricular dysfunction is associated with an increase in the risk of 
sudden death [74]. Few population-based data are available on secular trends in the prognosis of heart 
failure. In Framingham and Olmsted County, earlier studies reported no improvement in the survival 
of heart failure validated using Framingham criteria  [61,75]. More recently, improvement in the 
survival of hospitalized heart failure among the Scottish population was reported [71] with notable age 
and sex differences in the magnitude of the secular trends. Several explanations can be offered for 
these inconsistencies. Firstly, the data reported by McIntyre pertain to more recent years and may, as 
suggested by the authors, reflect in part the effectiveness of angiotensin converting enzyme inhibitors. 
However, the median survival improved relatively modestly from 1.2 to 1.6 years such that, while the 
large sample size (66,547 patients) results in high statistical significance, the clinical significance of 
this improvement in survival is more modest. Further, as acknowledged by the authors, the analyses 
relied solely on hospitalized cases, not validated, such that the improvement in outcome may be 
confounded by trends in coding practice and shifting of hospitalization thresholds.  
Regardless, these data resonate with clinical trial data that indicated that angiotensin converting 
enzyme inhibitors, while associated with large reductions in the relative risk of mortality, resulted in 
more modest (5.7%) absolute event-rate difference. [76] 
Conversely, the administrative data from the Henry Ford Health system, which include outpatient 
encounters, reported a median survival of 4.2 years without any discernible improvement over 
time [65]. These large discrepancies in survival estimates underscore the challenges in investigating 
the heart failure epidemic and help delineate key requirements for such evaluation. This investigation 
should include all cases of heart failure in a geographically defined population and use standardized 
validation criteria in order to generate valid longitudinal trends. These analyses should examine trends 
in hospital admission as an additional outcome as high hospital admission rates after diagnosis provide 
insights into the outcome of heart failure, independently of disease severity  [77-81], and are an 
important component of its public health burden. Despite notable improvements in survival over time, 
data from Framingham [68] and Olmsted County [67] underscored the persistently high mortality of 
heart failure even in more contemporary times: indeed, after age adjustment, estimated 5-year 
mortality rates were 59% in men and 45% in women during the time period 1990–1999 in 
Framingham and 50% in men and 46% in women during the time period 1996–2000 in Olmsted 
County. Improvements in survival were also noted more specifically within an elderly population as 
shown by data from the Kaiser Permanente system. Indeed, over the two decades between the mid 
1970’s and mid 1990’s after adjustment for age and comorbidities, survival after the diagnosis of heart 
failure improved by 33% in men and 24% in women [69]. Importantly, in the Kaiser Permanente study, 
improvement in survival was primarily associated with beta blocker treatment. Altogether, these data on 
mortality coincide temporally with major changes in the treatment of heart failure and thus reflect two 
key points; heart failure treatment is effective in the community but much progress remains to   
be accomplished.  
As discussed above, the data available suggest that the proportion of heart failure with preserved 
ejection fraction increased over time. As the survival of heart failure with preserved ejection fraction Int. J. Environ. Res. Public Health 2010, 7          
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remained unchanged [16], its prevalence can be assumed to be increasing thereby underscoring the 
growing importance of heart failure with preserved ejection fraction as a public health problem and the 
urgent need to define specific treatment for this entity [15].  
 
4.1. Cause of Death in HF  
 
While the causes of death in heart failure can be challenging to ascertain, there is evidence that, in 
the community and within the context of stable overall survival, cardiovascular deaths were less 
frequent among subjects with preserved ejection fraction. Indeed, in Olmsted County, Minnesota, 
among 1063 persons with heart failure, the leading cause of death in subjects with preserved ejection 
fraction was non-cardiovascular (49%) versus coronary disease (43%) for subjects with reduced 
ejection fraction. The proportion of cardiovascular deaths decreased from 69% in 1979–1984 to 40% 
in 1997–2002 (p = 0.007) among subjects with preserved ejection fraction contrasting with a modest 
change among those with reduced ejection fraction (77% to 64%, p = 0.08) [77]. The shift in the 
distribution of the causes of death towards less cardiovascular causes has important implications for 
the understanding of secular trends in heart failure, and for therapeutic trials for this condition. 
 
5. Hospital Admissions in Heart Failure 
 
As reviewed above, there is evidence that the incidence of heart failure has remained stable over the 
past 2 decades while survival has improved [65,67,68]. These findings indicate that the heart failure 
can be conceptualized as a large chronic disease epidemic with an increase in prevalence related to the 
aging of the population and the improved survival of patients with heart failure [65]. Both factors 
increase the number of candidates for hospital admissions. Given these epidemiological trends, it 
should not come as a surprise that, heart failure is the single most frequent cause of hospitalization in 
persons 65 years of age or older, and that hospital discharges for heart failure increased 157 percent 
between 1979 and 2002 [82]. These staggering numbers underscore the public health burden of heart 
failure as highlighted in the guidelines from the American Heart Association and American College of 
Cardiology [2]. As hospital admissions are the major driver of health care costs in heart failure [83], 
understanding the epidemiology of hospital admissions in heart failure, its determinants and 
significance for the outcome of the disease as assessed by the proportion specifically related to heart 
failure exacerbation is a necessity.  
As hospital admissions are event-based, this allows multiple hospitalizations for the same individual 
to be counted. Thus, this information, while crucial to assess the health care implications of heart 
failure, does not measure hospitalizations experienced by individual patients. Further, in administrative 
data, the diagnoses are not validated using standardized criteria, and shifts in hospital discharge 
diagnoses preferences after the introduction of the Diagnosis-Related Groups payment systems have 
been demonstrated  [55,56]. As mentioned above, for heart failure in particular, “upcoding” of 
discharge diagnoses related to reimbursement issues is well documented and quite large [57]. Thus, 
national statistics and claims data do not provide insight into the number of hospitalizations 
experienced by individual patients living with heart failure and how it may have changed over time. 
This is important as intense treatment efforts (medications, device and disease management-based) are Int. J. Environ. Res. Public Health 2010, 7          
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directed at reducing hospitalizations in heart failure, yet their effectiveness in the population remains 
to be documented by demonstrating a reduction in admissions over time. Moreover, heart failure is a 
chronic disease characterized by bouts of exacerbation leading to recurrent hospitalizations. Thus, 
measures of the frequency of heart failure-specific hospitalizations are essential to gain insight into the 
effectiveness of its treatment. Indeed, medications for heart failure cannot be expected to appreciably 
reduce all hospitalizations among persons with heart failure, given the high prevalence of comorbidity 
in these patients. Despite the importance of these issues, data on the frequency of hospital admissions 
among subjects with heart failure are relatively sparse and often incomplete as summarized in Table 4. 
Several observations stem from the review of this table. Firstly, there is little data, contrasting with the 
perceived magnitude of the problem. Studies are heterogeneous in many ways including setting, 
population studied, and criteria used to diagnose the index heart failure, and heart failure-related 
hospitalizations, which seldom included validation. Thus, not unexpectedly, their results   
lack consistency. 
All studies pertain to hospitalized cases and measure re-admissions. Yet, a large proportion of 
incident heart failure cases are diagnosed in outpatient settings such that the numbers reported do not 
pertain to the entire spectrum of patients with heart failure  [67]. Further, as these reports did not 
ascertain the incident status of heart failure, their results are affected by incidence prevalence bias, 
which limits their validity. Indeed, information from an incidence cohort is essential as the outcome of 
a disease cannot be interpreted if subjects at various stages in their evolution are combined. Despite the 
intuitive aspect of this point, this is not adequately addressed in previous publications. Additionally, 
few studies assessed secular trends, which is important given therapeutic efforts to improve survival 
and reduce hospitalizations in heart failure [84]. Those that did reported conflicting data. Moreover, 
the impact of death was not taken into account in these studies, which further hinders the validity of 
their results. Indeed, not accounting for the impact of death will lead to biased results by 
overestimating the incidence of non-fatal events in a population for which the death rate is higher than 
the general population as is the case for heart failure [85,86]. Importantly, data on heart failure-specific 
hospitalizations as opposed to all-cause hospitalizations are even sparser but suggest that heart failure-
specific hospitalizations may be noticeably less frequent. To this end, National Hospital Discharge 
Survey data from 1979 to 2004 indicate that whereas heart failure was the first-listed diagnosis for 
30% to 35% of these hospitalizations, the proportion with respiratory diseases and noncardiovascular, 
nonrespiratory diseases as the first-listed diagnoses increased  [54]. In the community of Olmsted 
County, among a random sample of all incident HF cases in Olmsted County, Minnesota, from 1987 to 
2006, hospitalizations were common after HF diagnosis, with 83% of the patients hospitalized at least 
once. The reason for hospitalization was HF in 17% of hospitalizations and other cardiovascular in 
22%, whereas 62% were non-cardiovascular [87]. It is important to characterize recurrent outcomes, 
like hospitalizations, in chronic diseases like heart failure, the outcome of which is characterized by 
recurrence/exacerbation. While the analysis of multiple events presents methodological challenges 
related in part to the correlation of these events, statistical techniques have been developed to address 
them [88-91]. These have the potential of providing new insight on the outcome of heart failure by 
characterizing patterns of hospitalizations and identifying subjects at risk for recurrent hospitalizations 
that should be offered aggressive preventive strategies.  Int. J. Environ. Res. Public Health 2010, 7          
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Table 4. Selected studies on hospitalizations among patients with heart failure. 
Author N  Year  Readmission  Readmission  for 
heart failure 
Data source  Definition 
criteria 
Temporal 
trends 
McDermott  [132]  612 
 
1987-93    13% at 6 months  Hospital in 
Chicago 
Dismissal 
diagnosis 
No change 
Krumholz  [7, 133]  17,448 
 
1991-94  44% at 6 
months 
---  Medicare files  DRG 127  --- 
Philbin EF  [134]  2906  1995-97  43% at 6 
months 
---  Hospitals in New 
York 
Admission and 
dismissal 
diagnoses 
--- 
Cowie MR  [135]  332  1996-97  59% at 19 
months 
--- Population-based 
in Scotland 
European 
Society of 
Cardiology  
--- 
Babayan  [136]  493 
 
1996-97  57% at 1 year  20% at 1 year  Johns Hopkins 
Hospital 
DRG 127  --- 
Smith  [137]  413  1996-98  46% at 6 
months 
19% at 6 months  New Haven 
hospital 
Clinical --- 
Baker  [138]  22,203 
 
1991-97  11% at 30 
days 
--- Medicare 
 
ICD 9 codes  Increase over 
time 
Lee WY  [139]  1700 
 
1999-2000  148 per 100 
person-years 
40 per 100 
person-years 
EPOCH Kaiser 
 
Framingham   ---- 
Lee DS  [140]  77,421 
 
1992-2002  ---  27% at 1 year  Administrative 
database in 
Ontario 
ICD 9 code 428  4 %/year 
decrease in 1 
year  
Badano  [141]  179  1999-2000  48% at 6 
months 
---  Hospitals in Italy  Clinical  --- 
Rodriguez-Artalejo 
 [142] 
394  2000- 2001  35% at 6 
months 
--- Hospitals  in 
Spain 
European 
Society of 
Cardiology  
--- Int. J. Environ. Res. Public Health 2010, 7          
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6. Etiology of Heart Failure—An Ongoing Controversy  
 
The guidelines underscore the challenge of assigning a cause to heart failure [2]. The etiology of 
heart failure is a complex issue and it should be approached while focusing on clinically ascertained 
risk factors while acknowledging that putative causes of heart failure often co-exist and interact. From 
a public health and prevention perspective, the determination of the prevalence of each respective 
cause as ascertained clinically is important because of the resulting clinical implications. For example, 
demonstrating an increase in the attributable risk of diabetes mellitus independently of clinical 
coronary disease would then prompt further investigations about the mechanisms whereby diabetes 
leads to heart failure in the absence of clinical coronary disease. Such mechanisms may include occult 
coronary disease, but within the appropriate analytical framework, would be distinct from clinically 
established coronary disease.  
The etiology of heart failure and how it may have changed over time is not defined. It is 
conceivable that the increasing burden of heart failure as measured by hospital admissions relates in 
part to changing etiology, the analyses of which should thus be part of the investigation of the heart 
failure epidemic and integrated with the analysis of coronary disease and hypertension trends. 
While research has focused on coronary disease and hypertension as the etiology of heart 
failure  [1], the obvious importance of defining the respective contribution of these two entities 
contrasts with the lack of knowledge in this regard. Moreover, the reported data are conflicting and 
secular trends have infrequently been examined. Yet, the population burden of putative risk factors for 
heart failure is changing in the population, such that the attributable risk of these risk factors for heart 
failure may change over time. Understanding the attributable risk of risk factors for heart failure and 
how it changes over time is crucial for prevention.  
Estimates of the  prevalence of coronary disease in studies of heart failure vary considerably. 
Fox [92], using angiography, concluded that coronary disease was causal in 52% of new heart failure 
cases under age 75 in a geographically defined population and that clinical assessment without 
angiography under-estimates the contribution of coronary disease to heart failure. However, few 
patients were over 75 years of age and only 73% underwent angiography. Thus, the inference from 
these data is limited by selection bias. Reviewing randomized trial data, Gheorgiade concluded the 
prevalence of coronary disease in heart failure was 68% [93]. However, important methodological 
considerations limit the inference that can be drawn form these data. Indeed, the limitations in external 
validity inherent to clinical trials may be even more apparent in heart failure trials, which typically 
include younger patients and more men than the general population of heart failure  [94,95]. 
Furthermore, entry criteria in heart failure trials are heterogeneous and seldom validated [96]. Finally, 
heart failure trials often require systolic left ventricular dysfunction  [94], thereby excluding a 
substantial proportion of heart failure cases [16,97]. Reviewing observational reports of patients with 
heart failure, Teerlink concluded that the prevalence of coronary disease in heart failure was 50% [98], 
and in yet another study, which was population-based in England and relied on a panel of physicians, 
Cowie reported that coronary disease was the etiology of heart failure in 36% of the cases [99]. These 
large discrepancies may reflect, in part, differences in populations and design. More importantly, they 
underscore our limited knowledge with regards to the etiology of heart failure, which   
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Data from the first National Health and Nutrition Examination Survey (NHANES I) indicate that 
coronary disease had the largest population attributable risk for heart failure at 62% compared to the 
other risk factors analyzed (hypertension, obesity, diabetes and smoking) [100]. The attributable risk of 
hypertension was 10% and that of diabetes was 3% due to its low prevalence. This likely 
underestimates, as acknowledged by the authors, the role of diabetes which was ascertained by   
self-report among patients enrolled more than 20 years ago with the incidence of diabetes mellitus 
increasing over time. In the Cardiovascular Health Study, the attributable risk of coronary disease and 
hypertension for heart failure were similar, between 12 and 13%, with a notable attributable risk of 8% 
for diabetes  [101]. The Framingham Heart Study traditionally underscored a large contribution of 
hypertension to heart failure [102-105]. More recently, however, it suggested a 41% increase in the 
prevalence of coronary disease and a 10% decrease in that of hypertension in heart failure  [106]. 
Whether the results of Framingham are generalizable to larger populations remains to be addressed, 
particularly in light of hypertension trends in the US and in Olmsted County discussed below. 
Therefore, whether the etiology of heart failure shifted from hypertension to coronary disease remains 
to be determined. To this end, when the contribution of coronary disease to heart failure and its 
hypothetical change over time is examined by analyzing population trends in coronary disease, the 
data are difficult to reconcile with the aforementioned hypothesis of an increasing contribution of 
coronary disease to heart failure. Indeed, several groups reported on secular trends in the incidence of 
myocardial infarction indicating that, overall, the burden of incident hospitalized myocardial 
infarction, while displaced towards older age groups, is not increasing  [107,108]. There is also 
evidence that the severity of myocardial infarction is decreasing [109] and that, consistent with these 
results, the incidence of heart failure after myocardial infarction is declining over time [110]. Taken 
collectively, these data are challenging to reconcile within the framework of the ongoing heart failure 
epidemic related to improved survival after myocardial infarction. While it is conceivable that more 
chronic forms of coronary disease could lead to heart failure without myocardial infarction, the role of 
chronic coronary disease in the genesis of heart failure is not defined. With regards to hypertension, 
conversely,  unfavorable trends in awareness, treatment and control of hypertension have been 
documented  [111,112]. Thus, coronary disease and hypertension trends in population studies both 
suggest that the attributable risk of hypertension for heart failure should remain high. To this end, 
Olmsted County data indicate that the risk of heart failure is greatest for coronary disease and diabetes, 
but that coronary disease and hypertension are responsible for the largest proportion of new heart 
failure cases in the population [113]. Over time, there was no evidence for a temporal change in the 
population attributable risk for heart failure of coronary disease, diabetes, and smoking. By contrast, 
the population attributable risk for hypertension increased from 15% (1979–1984) to 29% (1979–
2002), and for obesity from 8% (1979–1984) to 17% (1997–2002) [113]. Indeed, the rising tide of 
diabetes mellitus [114] and obesity [115] raise the concern of an increasing role of these two entities in 
the genesis of heart failure. Notwithstanding uncertainties with regards to the exact cellular and 
molecular mechanisms by which obesity and diabetes impact both systolic and diastolic left ventricular 
function, there is mounting evidence for their causal link to heart failure independently of clinical 
coronary disease and hypertension [116-120]. Thus, the growing burden of diabetes and obesity in the 
population suggest that these two risk factors may be increasingly contributing to the heart   
failure epidemic.  Int. J. Environ. Res. Public Health 2010, 7          
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7. Conclusion 
 
Despite the staggering impact of heart failure as measured by Vital Statistics and administrative 
databases, validated longitudinal data on the incidence and outcome of heart failure remain sparse. The 
available data indicate that the incidence of heart failure is overall stable in the predominantly white 
populations in which it was studied.  
Survival, which remains poor, is nevertheless improving over time. This results in an increase in the 
prevalence of heart failure and an increase in the number of individuals at risk for multiple 
hospitalizations. Future epidemiology research should investigate the heart failure epidemic in diverse 
populations and examine the burden and determinants of hospitalizations in heart failure. 
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